Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

the company announced the long-awaited approval of Cobenfy for the treatment of schizophrenia. In addition to its extremely ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Top 15. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...

The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic ...

The setback is a potential plus for Bristol Myers Squibb, which in September won Food and Drug Administration approval of Cobenfy, the first new kind of treatment for schizophrenia patients in decades ...

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...